R & d- medical: biomedical (basic research)

Ended Definitive Contract Awarded Last action

Contract number
HHSN261201400039C
Awardee
Awarding agency
Obligated
$224,997

Award facts

Opportunity
  • N432C04100527 Solicitation number
Contract value 100% obligated
$224,997.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 27 offers Basic Research
Pricing
Firm Fixed Price
Place of performance
Encino, CA 91316, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Supplemental Agreement for work within scope 1 $0
Original award $224,997

About this award

The National Cancer Institute awarded a $224,997.00 firm fixed-price definitive contract to Paganini Biopharma, Inc. for research and development in biomedical basic research. The contract has a performance period ending on September 17, 2015 and was awarded on September 18, 2014. This contract was not set aside for any specific business type. The National Cancer Institute is a civilian agency within the U.S. Department of Health and Human Services that conducts and supports cancer research.

Quick answers

Who was awarded contract HHSN261201400039C?

HHSN261201400039C was awarded to Paganini Biopharma, Inc. by National Cancer Institute (National Institutes of Health) on September 18, 2014.

How much is contract HHSN261201400039C worth?

The government has obligated $224,997 on HHSN261201400039C.

Was contract HHSN261201400039C competed?

The extent of competition for HHSN261201400039C was full and open competition. The government received 27 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award